Melanie Nimrodi, Media Contact 312.546.3508 mnimrodi@frbir.com At the Company: Robert McNally / Jennifer Nelms 404.727.0971 FOR IMMEDIATE RELEASE GeoVax Reports Progress On Its AIDS Vaccine Technology ATLANTA, G

GeoVax Reports Progress On Its AIDS Vaccine Technology

ATLANTA, GA, July 7, 2008 GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta based, publicly traded

biopharmaceutical company specializing in the prevention and treatment of infectious diseases,

today provided an operational update on the company s progress towards entering Phase 2

preventative human clinical trial testing and plans to proceed into therapeutic human trials with

its AIDS vaccine. Five successful human trials evaluating GeoVax AIDS vaccines have previously been

Planned Phase 2 Human Clinical Trial for Prevention of AIDS

The Company s Phase 2 trial, conducted by the U.S. National Institutes of Health (NIH) supported

HIV Vaccine Trials Network (HVTN), will involve 225 healthy volunteers from the United States and

South America, and will further evaluate the safety and immunogenicity of the GeoVax preventative

vaccine (vaccine administered prior to infection with the HIV virus). In Phase 1 trials, both

1/10th dose and full dose of the GeoVax vaccine elicited anti-HIV T-cells, whereas the

full dose was required to elicit good frequencies of antibody to the HIV Envelope glycoprotein. The

larger Phase 2 human trial will broaden the base of safety and immunogenicity data for the full

dose of the GeoVax AIDS vaccine with a view to protecting recipients from developing AIDS should

they be exposed to the virus. The planned Phase 2 human clinical trial is currently scheduled to

start early this fall, subject to FDA approval.

Preclinical Data for Use of Vaccine Technology as an AIDS Therapeutic

Human Clinical Trials in Planning Stages

GeoVax also announced summary data from a pilot study on therapeutic vaccination in simian

immunodeficiency virus (SIV) infected non-human primates with the SIV prototype for the GeoVax AIDS

vaccine. In this small pilot study, conducted by Dr. Amara at Emory University, two non-human

primates were infected with SIV. At 12 weeks post SIV infection, conventional anti-viral drug

therapy was given to the primates to reduce the viral RNA infection levels to very low levels

creating a non progressor status for the primate. Then the SIV prototype vaccine for the GeoVax

AIDS vaccine was administered. Six weeks following the final vaccination, anti-viral drug treatment

was stopped and the animals were monitored to determine whether the vaccine could control the SIV

infection during the absence of the drugs.

The outstanding results from the study revealed the vaccine controlling the infection in the

absence of drugs. In one primate, the reduction in viral levels over pre-drug treatment and

vaccination levels was 1000 times. In the other, the reductions in viral levels were 100 times. The

excellent control of the

virus infection in the absence of drug treatment was associated with the vaccine raising the types

of CD4 and CD8 T cells that are found in the rare individuals who spontaneously control their HIV

Based on these excellent results, planning for a therapeutic trial in infected and drug treated

humans has been initiated. The intent of therapeutic vaccination is for the vaccine to control

HIV virus levels in infected individuals to very low levels thus blocking the development of AIDS.

Successful therapeutic AIDS vaccination programs with GeoVax vaccines would lead to reduction in

the use of costly anti-HIV medications and their often harmful side effects.

Dr. Harriet Robinson, GeoVax Co-founder and Senior V.P. of Research and Development, commented, I

had not anticipated the extent of vaccine control that was achieved in the already infected

non-human primates. These are highly promising results that need to be extended into infected

humans to see if the vaccine can be used to reduce the need for taking drugs. The results also

warrant more extended studies in already infected non-human primates to explore parameters that

both limit and enhance the ability for a vaccine to displace the need for drugs.

Dr. Robert McNally, CEO and President of GeoVax Labs, Inc., emphasized, It is noteworthy to

mention that the GeoVax AIDS vaccines being tested in the preclinical therapeutic trial is the same

basic vaccine administered in the Company s human trials testing for a preventative use of the

vaccine, vaccinating people before infection to prevent the development of AIDS should they become

infected. Thus, a one for two vaccine could be a breakthrough solution for the company and the

world, saving millions of dollars in redundant development costs and years of testing time by

utilizing safety data already achieved in Phase 1 preventative human trials. More important, time

to market could be significantly reduced, saving lives much sooner than otherwise.

Further, GeoVax s management is pleased to report that the company is currently engaged in

negotiations with a NIH sponsored trial network to administer, conduct and co-sponsor GeoVax s

Therapeutic human trial program. Management expects to receive approval for undertaking formal

protocol development in the near future and will report more detailed plans accordingly.

From an operational standpoint, we are very pleased with the overall progress of the company,

stated Dr. Robert McNally. Progress with ongoing preventative vaccine trials and now the potential

to address therapeutic use of the vaccine gives GeoVax an expanding role in the fight to control

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and

commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other

infectious agents. GeoVax s AIDS vaccine technology is the subject of 20 issued or filed patent

applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired

Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become

infected. GeoVax AIDS vaccines also may be effective as therapeutics, treatment of people

already infected with AIDS virus.

GeoVax s core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of

Research and Development, through a collaboration of colleagues at Emory University s Vaccine

Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention

GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine

Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative

agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials

program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling

evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided

additional support to GeoVax AIDS vaccine development program with a $15 million IPCAVD grant

awarded in late 2007.

Safe Harbor Statement: All statements in this news release, not statements of historical fact, are

forward-looking statements. These statements are based on expectations and assumptions on the date

of this press release and are subject to numerous risks and uncertainties which could cause actual

results to differ materially from those described in the forward-looking statements. Risks and

uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these

vaccines with the desired characteristics in a timely manner, GeoVax s vaccines will be safe for

human use, GeoVax s vaccines will effectively prevent AIDS in humans, vaccines will receive

regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to

complete vaccine development, there is development of competitive products that may be more

effective or easier to use than GeoVax s products, and other factors over which GeoVax has no

control. GeoVax assumes no obligation to update these forward-looking statements, and does not

intend to do so. Certain matters discussed in this news release are forward-looking statements

involving certain risks and uncertainties including, without limitation, risks detailed in the

Company s Securities and Exchange Commission filings and reports.

* * * * * * * * * * * * * * *